ACR20 response

Group by Anti-TNF	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Control
Adalimumab	Weinblatt et al. 2003 (29)	4.15	2.25	7.67	126 / 209	9 / 62
Adalimumab	van de Putte et al, 2004 (30)	2.28	1.53	3.40	189 / 434	21 / 110
Adalimumab	Furst et al, 2003 (31)	1.52	1.27	1.83	169 / 318	111 / 318
Adalimumab	Keystone et al, 2004 (32)	2.37	1.82	3.07	238 / 419	48 / 200
Adalimumab	Breedveld et al, 2006 (33)	1.01	0.90	1.13	344 / 542	162 / 257
Adalimumab		1.89	1.30	2.75		
Etanercept	Moreland et al, 1999 (24)	4.79	2.54	9.02	83 / 154	9 / 80
Etanercept	Weinblatt et al, 1999 (25)	2.67	1.44	4.94	42 / 59	8 / 30
Etanercept	Bathon et al, 2000 (26)	1.11	0.97	1.26	149 / 207	141 / 217
Etanercept	van der Heijde et al 2006 (28)	1.07	0.98	1.17	365 / 454	171 / 228
Etanercept		2.06	1.11	3.86		
Infliximab	Lipsky et al, 2000 (19)	4.14	2.00	8.57	112 / 340	7 / 88
Infliximab	St Clair et al, 2004 (20)	1.18	1.05	1.33	480 / 751	161 / 298
Infliximab	Quinn et al, 2005 (22)	1.33	0.74	2.41	8 / 10	6 / 10
Infliximab	Westhovens et al, 2006 (23)	2.34	1.93	2.84	404 / 721	87 / 363
Infliximab		1.82	1.19	2.77		
Overall		1.81	1.43	2.29		

Risk ratio and 95% CI



ACR50 response

Group by Anti-TNFα	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Control
Adalimumab	Weinblatt et al, 2003 (29)	5.34	2.27	12.55	90 / 209	5 / 62
Adalimumab	van de Putte et al, 2004 (30)	2.93	1.53	5.60	104 / 434	9 / 110
Adalimumab	Furst et al, 2003 (31)	2.66	1.86	3.79	93 / 318	35 / 318
Adalimumab	Keystone et al, 2004 (32)	4.17	2.68	6.50	166 / 419	19 / 200
Adalimumab	Breedveld et al, 2006 (33)	1.12	0.96	1.31	278 / 542	118 / 257
Adalimumab		2.68	1.58	4.56		
Etanercept	Moreland et al, 1999 (24)	6.36	2.38	17.00	49 / 154	4 / 80
Etanercept	Weinblatt et al, 1999 (25)	11.69	1.66	82.47	23 / 59	1 / 30
Etanercept	Bathon et al, 2000 (26)	1.14	0.93	1.40	101 / 207	93 / 217
Etanercept	van der Heije et al, 2006 (28)	1.39	1.17	1.65	266 / 454	96 / 228
Etanercept		2.11	1.10	4.04		
Infliximab	Lipsky et al, 2000 (19)	4.14	2.00	8.57	112 / 340	7 / 88
Infliximab	St Clair et al, 2004 (20)	1.50	1.25	1.80	360 / 751	95 / 298
Infliximab	Quinn et al, 2005 (22)	2.00	0.88	4.54	8 / 10	4 / 10
Infliximab	Westhovens et al, 2006 (23)	3.49	2.48	4.92	229 / 721	33 / 363
Infliximab		2.51	1.38	4.57		
Overall		2.46	1.75	3.45		

Risk ratio and 95% CI



ACR70 response

Group by Anti-TNF	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Group-B
Adalimumab	Weinblatt et al. 2003 (29)	3.86	1.23	12.05	39 / 209	3 / 62
Adalimumab	van de Putte et al, 2004 (30)	6.72	1.66	27.13	53 / 434	2 / 110
Adalimumab	Furst et al, 2003 (31)	4.73	2.43	9.19	47 / 318	10 / 320
Adalimumab	Keystone et al, 2004 (32)	4.88	2.51	9.47	92 / 419	9 / 200
Adalimumab	Breedveld et al. 2006 (33)	1.28	1.02	1.60	194 / 542	72 / 257
Adalimumab		3.33	1.76	6.29		
Etanercept	Moreland et al, 1999 (24)	9.35	1.27	68.78	18 / 154	1 / 80
Etanercept	Weinblatt et al, 1999 (25)	9.82	0.59	163.15	9 / 59	0 / 30
Etanercept	Bathon et al, 2000 (26)	1.15	0.81	1.62	52 / 207	47 / 215
Etanercept	van der Heije et al, 2006 (28)	1.79	1.33	2.41	153 / 454	43 / 228
Etanercept		2.02	0.92	4.40		
Infliximab	Lipsky et al, 2003 (19)	9.96	2.50	39.77	77 / 340	2 / 88
Infliximab	St Clair et al, 2004 (20)	1.68	1.32	2.14	263 / 751	62 / 298
Infliximab	Quinn et al, 2005 (22)	2.33	0.83	6.54	7 / 10	3 / 10
Infliximab	Westhovens et al, 2006 (23)	3.21	1.92	5.35	102 / 721	16 / 363
Infliximab		2.86	1.41	5.78		
Overall		2.77	1.85	4.15		

Risk ratio and 95% CI